Vir Biotechnology (NASDAQ:VIR) Given “Buy” Rating at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Vir Biotechnology (NASDAQ:VIR) in a research note issued to investors on Friday,Benzinga reports. They currently have a $110.00 price target on the stock. HC Wainwright also issued estimates for Vir Biotechnology’s Q1 2026 earnings at ($0.80) EPS, Q2 2026 earnings at ($0.80) EPS, Q3 2026 earnings at ($0.81) EPS and Q4 2026 earnings at ($0.77) EPS.

VIR has been the subject of a number of other research reports. Leerink Partners boosted their price target on Vir Biotechnology from $18.00 to $20.00 and gave the company an “outperform” rating in a research note on Monday, January 13th. Needham & Company LLC reaffirmed a “buy” rating and issued a $19.00 price target on shares of Vir Biotechnology in a research note on Thursday. JPMorgan Chase & Co. boosted their price target on Vir Biotechnology from $10.00 to $14.00 and gave the company a “neutral” rating in a research note on Thursday, January 9th. Barclays dropped their price target on Vir Biotechnology from $28.00 to $26.00 and set an “overweight” rating for the company in a research note on Monday, November 4th. Finally, Morgan Stanley raised Vir Biotechnology from an “equal weight” rating to an “overweight” rating and boosted their price target for the company from $10.00 to $20.00 in a research note on Thursday, January 9th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $35.67.

Vir Biotechnology Stock Performance

Shares of Vir Biotechnology stock opened at $8.39 on Friday. The firm has a 50-day moving average of $9.46 and a 200-day moving average of $8.49. The stock has a market cap of $1.16 billion, a PE ratio of -2.14 and a beta of 0.63. Vir Biotechnology has a 52-week low of $6.56 and a 52-week high of $14.45.

Vir Biotechnology (NASDAQ:VIR) last announced its earnings results on Wednesday, February 26th. The company reported ($0.76) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.85) by $0.09. The company had revenue of $12.37 million during the quarter, compared to analysts’ expectations of $8.14 million. Vir Biotechnology had a negative net margin of 678.40% and a negative return on equity of 36.71%. Equities research analysts predict that Vir Biotechnology will post -3.92 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, EVP Verneuil Vanina De sold 7,373 shares of the company’s stock in a transaction that occurred on Wednesday, February 26th. The stock was sold at an average price of $9.14, for a total value of $67,389.22. Following the completion of the transaction, the executive vice president now owns 79,460 shares of the company’s stock, valued at $726,264.40. This represents a 8.49 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director George A. Scangos sold 10,964 shares of the company’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $9.81, for a total value of $107,556.84. Following the completion of the transaction, the director now directly owns 708,295 shares of the company’s stock, valued at $6,948,373.95. This represents a 1.52 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 30,935 shares of company stock valued at $327,082. 15.60% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in VIR. Blue Trust Inc. boosted its holdings in Vir Biotechnology by 143.5% in the third quarter. Blue Trust Inc. now owns 3,989 shares of the company’s stock valued at $30,000 after acquiring an additional 2,351 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new stake in Vir Biotechnology in the fourth quarter valued at approximately $42,000. SBI Securities Co. Ltd. bought a new stake in Vir Biotechnology in the fourth quarter valued at approximately $60,000. PNC Financial Services Group Inc. boosted its holdings in Vir Biotechnology by 31.8% in the fourth quarter. PNC Financial Services Group Inc. now owns 8,288 shares of the company’s stock valued at $61,000 after acquiring an additional 1,999 shares during the last quarter. Finally, KBC Group NV boosted its holdings in Vir Biotechnology by 136.5% in the fourth quarter. KBC Group NV now owns 8,970 shares of the company’s stock valued at $66,000 after acquiring an additional 5,177 shares during the last quarter. Institutional investors and hedge funds own 65.32% of the company’s stock.

About Vir Biotechnology

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).